RIPK3 and metabolic dysfunction-associated steatohepatitis: Alfonso et al.87 have used IHC on human livers with various diseases and have demonstrated an increase in RIPK3 staining in liver sections from humans with NASH, ASH and hepatitis B and C. One could interpret this one of two ways, either all of these human liver diseases result in RIPK3 upregulation and as the authors suggest an involvement of necroptosis, or the antibody is non-specifically binding injured liver tissue.